RTB 101

Drug / Medication

A dual kinase inhibitor, also an mTOR inhibitor, studied in combination with everolimus and alone for improving immune function in older adults. Its phase 3 trial failed to hit its endpoint.

Mentioned in 1 video

Videos Mentioning RTB 101

175 - The biology of aging, rapamycin, and other interventions that target the aging process

175 - The biology of aging, rapamycin, and other interventions that target the aging process

Peter Attia MD

A dual kinase inhibitor, also an mTOR inhibitor, studied in combination with everolimus and alone for improving immune function in older adults. Its phase 3 trial failed to hit its endpoint.